Katsutoshi Tokushige1, Hideyuki Hyogo2, Tomoaki Nakajima3, Masafumi Ono4, Takumi Kawaguchi5, Koichi Honda6, Yuichiro Eguchi7, Yuichi Nozaki8, Miwa Kawanaka9, Saiyu Tanaka10, Kento Imajo11, Yoshio Sumida12, Yoshihiro Kamada13, Hideki Fujii14, Yasuaki Suzuki15, Tomomi Kogiso16, Yoshiyasu Karino3, Kensuke Munekage4, Ryoko Kuromatsu5, Satoshi Oeda7, Mikio Yanase8, Kohjiro Mori10, Yuji Ogawa11, Yuya Seko12, Tetsuo Takehara13, Yoshito Itoh12, Atsushi Nakajima11, Kazuyuki Kanemasa10, Ken Nishino9, Naohiko Masaki8, Hirokazu Takahashi7, Masataka Seike6, Takuji Torimura5, Toshiji Saibara4, Joji Toyota3, Kazuaki Chayama2, Etsuko Hashimoto16. 1. Department of Internal Medicine and Gastroenterology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan. ktoku@pg7.so-net.ne.jp. 2. Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan. 3. Department of Hepatology, Sapporo Kosei General Hospital, Hokkaido, Japan. 4. Department of Gastroenterology and Hepatology, Kochi Medical School, Kochi, Japan. 5. Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan. 6. Department of Gastroenterology, Faculty of Medicine, Oita University, Oita, Japan. 7. Division of Hepatology, Liver Center, Saga Medical School, Saga, Japan. 8. Department of Gastroenterology, National Center for Global Health and Medicine, Tokyo, Japan. 9. General Internal Medicine 2, Kawasaki Hospital, Kawasaki Medical School, Okayama, Japan. 10. Center for Digestive and Liver Diseases, Nara City Hospital, Nara, Japan. 11. Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan. 12. Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan. 13. Department of Gastroenterology and Hepatology, Osaka University, Graduate School of Medicine, Osaka, Japan. 14. Department of Gastroenterology, Osaka City Juso Hospital, Osaka, Japan. 15. Department of Gastroenterology, Nayoro City General Hospital, Hokkaido, Japan. 16. Department of Internal Medicine and Gastroenterology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.
Abstract
BACKGROUND: In Japan, the prevalence of hepatocellular carcinoma (HCC) associated with nonviral liver disease, especially with nonalcoholic fatty liver disease (NAFLD-HCC) and alcoholic liver disease (ALD-HCC), has been increasing. Clarification of the clinical features of NAFLD-HCC and ALD-HCC is needed. We performed a large retrospective multicenter survey to clarify the clinical course of these two types of HCC. METHODS: Clinical characteristics, survival, and recurrence were examined in 532 patients with ALD-HCC and 209 patients with NAFLD-HCC who were diagnosed between January 2000 and December 2013. RESULTS: The ALD-HCC patients were predominantly male and were younger than the patients with NAFLD-HCC. Lifestyle-related diseases were significantly more common in the NAFLD-HCC group, but the prevalence of cirrhosis was significantly higher in the ALD-HCC group. The histological diagnosis of NAFLD-HCC showed a gender difference (F4; 72.7 % in the females vs. 37.6 % in the males). The characteristic features of HCC including histology, survival rate, and recurrence rate were quite similar in the NAFLD-HCC and ALD-HCC groups: 5-year survival rates 49.1 vs. 43.7 %; 5-year recurrence rates 69.6 vs. 65.4 %, respectively. However, the risk factors for recurrence differed between the two groups: des-gamma-carboxy prothrombin was a risk factor in NAFLD-HCC and α-fetoprotein was a risk factor in ALD-HCC. CONCLUSIONS: Although the characteristic features underlying these two diseases are different, the two HCC groups showed a similar clinical course. The recurrence rates of the two HCC groups were relatively high. We found that critical tumor markers for recurrence differed between the two diseases.
BACKGROUND: In Japan, the prevalence of hepatocellular carcinoma (HCC) associated with nonviral liver disease, especially with nonalcoholic fatty liver disease (NAFLD-HCC) and alcoholic liver disease (ALD-HCC), has been increasing. Clarification of the clinical features of NAFLD-HCC and ALD-HCC is needed. We performed a large retrospective multicenter survey to clarify the clinical course of these two types of HCC. METHODS: Clinical characteristics, survival, and recurrence were examined in 532 patients with ALD-HCC and 209 patients with NAFLD-HCC who were diagnosed between January 2000 and December 2013. RESULTS: The ALD-HCCpatients were predominantly male and were younger than the patients with NAFLD-HCC. Lifestyle-related diseases were significantly more common in the NAFLD-HCC group, but the prevalence of cirrhosis was significantly higher in the ALD-HCC group. The histological diagnosis of NAFLD-HCC showed a gender difference (F4; 72.7 % in the females vs. 37.6 % in the males). The characteristic features of HCC including histology, survival rate, and recurrence rate were quite similar in the NAFLD-HCC and ALD-HCC groups: 5-year survival rates 49.1 vs. 43.7 %; 5-year recurrence rates 69.6 vs. 65.4 %, respectively. However, the risk factors for recurrence differed between the two groups: des-gamma-carboxy prothrombin was a risk factor in NAFLD-HCC and α-fetoprotein was a risk factor in ALD-HCC. CONCLUSIONS: Although the characteristic features underlying these two diseases are different, the two HCC groups showed a similar clinical course. The recurrence rates of the two HCC groups were relatively high. We found that critical tumor markers for recurrence differed between the two diseases.
Authors: M Ohhira; H Saito; Y Suzuki; T Naraki; S Sakurai; T Ohtake; M Suzuki; M Ohhira; Y Fujimoto And; Y Kohgo Journal: Alcohol Clin Exp Res Date: 2001-06 Impact factor: 3.455
Authors: Mohammed Eslam; Shiv K Sarin; Vincent Wai-Sun Wong; Jian-Gao Fan; Takumi Kawaguchi; Sang Hoon Ahn; Ming-Hua Zheng; Gamal Shiha; Yusuf Yilmaz; Rino Gani; Shahinul Alam; Yock Young Dan; Jia-Horng Kao; Saeed Hamid; Ian Homer Cua; Wah-Kheong Chan; Diana Payawal; Soek-Siam Tan; Tawesak Tanwandee; Leon A Adams; Manoj Kumar; Masao Omata; Jacob George Journal: Hepatol Int Date: 2020-10-01 Impact factor: 6.047